IBI-3034

N/A

Report date: 2025/12/04 10:43:39

Base Information

Drug NameIBI-3034
Drug Alias NameIBI-3034
ClassificationBiologics > Protein drugs > Recombinant protein > Fusion protein
Mechanisms of ActionB-cell maturation protein inhibitorsTumor necrosis factor receptor superfamily member 13B inhibitors
TargetsB-cell maturation proteinTumor necrosis factor receptor superfamily member 13B
Therapy Area/IndicationsAutoimmune DiseasesArthritis, Rheumatoid
Global Approved IndicationsN/A
Approved Indications in ChinaN/A
Original Approved Country/TerritoryN/A
Original Approved DateN/A
Country/TerritoryMainland China
CombinationsNo
Global Highest StatusPreclinical
Highest Status in ChinaPreclinical
Originator CompaniesInnovent Biologics(Suzhou) Co Ltd
China Registration ClassN/A

Develop Information

Active CompaniesInnovent Biologics(Suzhou) Co Ltd
Inactive CompaniesN/A
Active IndicationsAutoimmune DiseasesArthritis, Rheumatoid
Inactive IndicationsN/A

Other Information

ATC CodeN/A
Related LinksN/A